Date: 9-13-21

Benzinga.com

Cannabinoids: Today’s  Bio Revolution The production of cannabinoids—in our view—represents a flagship application for bio driven processes: highly valued, low (but growing) volume molecules that are difficult to access in nature, but demanded by large global markets for a massive diversity of enduses. And, we stand at the perfect moment in history: a beautiful era of computational, mechanical, and biological technology convergence.

Date: 9-13-21

Benzinga.com

Biomedican is the leader in Biosynthesized Cannabinoid Technology producing significantly better results, Higher yields, Higher quality, less time and less costs “We will be able to produce Rare cannabinoids for less than a gram. Which is the competitors in this space will be around 5-12 dollars a gram. We produce 99% pharmaceutical grade, Organic, Bioindetical Cannabinoids at 70-90% less costs”  With these new innovations, THCV will become a more frequent and less expensive presence in the cannabinoid market. Soon, THCV will be the target of large distribution networks at both online and retail locations in nutraceuticals, cosmetics, and skincare, with all these industries adding THCV to their existing product lines or developing new product lines around it.

Date: 8-21-21

hbw.pharmaintelligence.informa.com

BioMedican needs support until it can begin generating revenues and conduct an IPO. Businesses already marketing cannabinoid supplements receive more funding, or in some cases are acquired, as well as expand distribution.

Date: 8-11-21

spotify.com

In a recent podcast, Dennis O’Neill, President of BIOMEDICAN, Inc. discussed the health benefits associated with rare cannabinoids produced by BIOMEDICAN, Inc. These biosynthesized cannabinoids are 100% organic, pure, and pharmaceutical grade.

Date: 8-05-21

Youtube.com

Dennis O’Neill is the President at Biomedican, a biotech start-up company which developed a unique patented method of producing non-GMO rare cannabinoids like CBG, CBGA and THCV, THCVA.

Date: 8-05-21

missionmatters.com

In contrast to chemically synthesized compounds, our natural, 100% organic, non-GMO biosynthetic products are identical to those extracted from plants while offering higher purity than typically found in nature. Besides, the unique proprietary yeast is optimized to produce higher quantities of products at a lower cost than competing biosynthetic methods.

Date: 7-24-21

Youtube.com

Biomedican President Dennis O’Neill in Red, White, and Truth talks about CBD – market opportunities, new production methods such as biosynthesis, modern technologies, and the compound’s health benefits.

Date: 7-27-21

gooddudesgrow.com

With four patents pending, BioMediCan’s biosynthesis platform synthesizes rare cannabinoids through a fermentation process akin to brewing beer with four patents pending. The end result? Ninety-nine percent of pharmaceutical-grade cannabinoids are bio-organic, non-GMO, 70-90% less expensive than current market prices, requiring 90% less natural resources and energy.

Date: 7-24-21

pharmacytimes.com

O’Neill explained that the surge in research assessing the health potential for rare cannabinoids started with cannabidiol (CBD). Once companies saw the significant consumer interest in CBD, greater interest was raised in the potential benefits other cannabinoids could have.

Date: 7-17-21

pharmacytimes.com

“Research has shown that [CBG] significantly reduces intraocular pressure caused by glaucoma, and [cannabis] strains high in CBG may be beneficial in the treatment of inflammatory bowel disease, Crohn disease, and cancer, and it may have some benefits in treating anxiety,” O’Neill said.

Date: 7-20-21

Totalpharmacy.com

We have successfully biosynthesized CBG, CBGA, THCV, THCVA. And they have very, very significant health benefits, which are significantly better than CBD. And that’s where the markets going. And that will be the next generation going into these markets.

Date: 7-13-21

observer.com

The biosynthesis approach cuts the plant out of the equation and focuses on cannabis’ molecular machinery to dial up the production of rare cannabinoids. The end result is an isolated form of a rare cannabinoid. It’s the same product that would occur in nature, but without the additional terpenes or other molecules present in a plant (a downside some weed connoisseurs might say, but one that the emerging industry sees as an advantage).

Date: 6-12-21

Maximumyeild.com

Biomedican alludes to the fact the traditional way of producing rare cannabinoids through plants — interrupted production cycles with varying limited yield — is now passé, superseded by the biosynthesis method of manipulating organisms to produce select compounds as pharmaceutical giant Eli Lilly did in managing bacteria and yeast in order to manufacture insulin.

Date: 6-17-21

cannabisreportworld.com

Producing cannabis compounds having multibillion-dollar businesses and enormous therapeutic potential was challenging for scientists. Besides medical benefits, plant cannabinoids have associated toxic effects. The cannabis plant naturally releases its cannabinoids in oil droplets to curb these toxic effects. More the oil produced, more cannabinoids concentration. Biomedican overthrew this challenge with Yarrowia Lypolitica (YL), which produces oily drops inside their cells. Our scientists genetically engineered the Yarrowia Lypolitica (YL) strain that “ produces up to 80% of its weight in oils”. These oil droplets hold more quantity of cannabinoids than other non-oily yeasts.

Date: 5-12-21

headmagazine.com

Producing pharmaceutical psychedelics takes a very specialized knowledge to be successful. Management is what all successful investors look at first before investing because once you have identified a viable technology, the next biggest risk is execution. This is where most companies fail. Experienced management teams with a track record of success are much better equipped to be able to modify, optimize or pivot to deliver a successful outcome.

Date: 5-05-21

cannabisradio.com

The future of cannabis is in rare cannabinoids such as CBG, CBN, THCV, THCA, and more, said Dennis O’Neill, president of BioMedican, a biotech company that has developed a unique patented method of producing pharmaceutical-grade cannabinoids.

Date: 4-22-21

pharmacytimes.com

“It was mostly taken as a recreational drug to get high, and then some people receive some benefits from that. In the 60s and 70s, there was some research done that really showed some health benefits going into this. But the real problem that we have going on today is that we went from a COVID-19 pandemic to a mental health care epidemic, and now we have millions upon millions of people suffering from major mental health issues, and the system is being just overwhelmed by the amount of people that need real help,” O’Neill said.

Date: 4-27-21

medpagetoday.com

All cannabinoids originate from CBG, but the compound is present in only very small quantities (often less than 1%) of naturally-harvested cannabis. CBG could treat anxiety, pain, inflammation, and nausea, among other potential uses.

Date: 4-12-21

arizonafoothillsmagazine

There are cannabinoid receptors all over your skin. In every layer of it, including the skin’s surface (epidermis), oil glands (sebaceous glands), hair follicles, nerves, immune cells, and subcutaneous fat. Because of this, cannabis skincare can aid in the healing of at least 14 common skin issues.

Date: 3-29-21

spglobal.com

“With political tensions and the restrictions on moving money outside of China or Hong Kong, it makes it easier for Asian investors if the stock is listed on the Hong Kong exchange,” Dennis O’Neill, CEO of O’Neill Capital Advisors and president of BioMediCan Inc, told S&P Global Market Intelligence.

Date: 3-24-21

Chemistry world.

Max Mikheev, chief executive and chief science officer of Biomedican, a US-based start-up that produces rare cannabinoids using synthetic biology, says business and finance aren’t his favourite aspects of the job.

Date: 3-25-21

healthcarebusinesstoday.

BIOMEDICAN entered into the Astaxanthin market to diversify its products and show that its biosynthesis platform can target any high-value compound that has a significant market. We needed to do something new so that we weren’t overly concentrated on just the cannabinoid market. We analyzed what we had in search for the next big compound. Sometimes you have a valuable asset but even don’t recognize it.

Date: 3-15-21

Open Ganja

Biosynthesis is the production of the desired compound through the natural means of an organism’s biological processes. It produces identical compounds to those found in nature, lending itself as the optimal pathway for the manufacture of cannabinoids identical to their naturally occurring counterparts. ​

Date: 3-15-21

wphealthcarenews

Through biosynthesis, pharmaceutical companies are uniquely positioned to be a major player in the cannabinoid space. One reason is that biosynthesis makes rare cannabinoids cheaper and safer, giving pharmaceutical companies more incentive to use them, and another reason is pharmaceutical companies can get insurance reimbursement.

Date: 3-12-21

cannabis industry journal.

With climate change increasingly becoming a concern, it’s crucial for us to rely on more environmentally friendly avenues for cannabinoid production. Biosynthesis provides a method of cannabinoid production that requires significantly less time, energy and natural resources than cultivation through plants—resulting in not only a decreased environmental footprint but also safer and less expensive products.

Date: 2-26-21

Pharmaintelligence

Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.

Date: 2-26-21

pharmaintelligence.informa.com

BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.

Date: 2-26-21

tickertape

Investors looking for major winners in the space also run the risk of buying into major losers as the cannabis market becomes commoditized, increasing the importance of high quality and low price, according to O’Neill. “Only the best operators will be able to compete under these market conditions,” he pointed out.

Date: 2-17-21

CannabisIndustryJournal

Research shows rare cannabinoids are poised to be the future of cannabis investing, providing better health benefits in addition to impacting the pharmaceutical, CPG, nutraceuticals, cosmetics and pet care markets significantly. According to recent reports, the biosynthesis of rare cannabinoids will be a $25 billion market by 2025 and $40 billion by 2040.

Date: 2-9-21

biofuelsdigest

Biosynthesis is the production of the desired compound through the natural means of an organism’s biological processes. It produces identical compounds to those found in nature, lending itself as the optimal pathway for the manufacture of cannabinoids and carotenoids identical to their naturally occurring counterparts.

Date: 1-25-21

thefreshtoast

New investors may want to take notice of the cannabis market and its potential for lucrative gains. Two common options are proving beneficial for numerous stock market participants. Investing in cannabis stocks could be a fruitful effort for wise investors who can pinpoint the next big thing. On the other hand, experts say that exchange-traded funds (ETFs) could provide gains without the same work level for the less savvy investor.

Date: 1-21-21

ceocfointerviews

With biosynthesis we produce the exact same molecule each and every time and we can do it at significantly less cost but we also utilize 90% less energy and natural resources which makes this a sustainable model to where we are not burning up massive amounts of natural resources and energy as part of the process. As long as it is organic and bioidentical, about 90% of the market is in full support of it.

Date: 1-21-21

Maxim

The Biden administration will be much more accommodating and ultimately will legalize cannabis on a federal level, although these changes won’t happen overnight. All of this means significantly more investment into the cannabis market, so these stocks will perform exceptionally well.

Date: 1-21-21

thefreshtoast.com

Investors believe stocks at ETFs will continue to flourish in the years to come with America embracing a slightly more liberal-leaning federal government.
The global cannabis market is ballooning and should continue to inflate more in the coming years. Recent reports suggest that the global market could reach a value of $73.6 billion by 2027.

Date: 1-19-21

Nutraingredients

Fermentation specialist Biomedican plans to spin off a subsidiary that will be focused on astaxanthin production via a bioengineered yeast, the company said recently.

Date: 1-19-21

rollingstone.com

From a molecular perspective, Delta-9-THC and Delta-8 aren’t that different. Except for that, a particular chemical bond appears on the eighth carbon — instead of the ninth. Dr. Peter Grinspoon, an instructor in medicine at Harvard Medical School, estimates Delta-8 “has a portion but not all of the psychoactivity as Delta-9,” which is the majority opinion in the cannabis industry.

Date: 1-18-21

Benzinga

Cannabis sales in Michigan hit $984.6 million in 2020. Medical cannabis sales accounted for $474 million for the year, while adult-use sales reached $510.7 million.

Rhode Island and the Soboba Band of Luiseno Indians received approvals from the U.S. Department of Agriculture (USDA) for its hemp regulatory proposals.

Date: 1-18-21

YahooFinance

The Christmas and New Year’s holidays marked the single biggest cannabis sales period of 2020. The period between Dec. 18 and Dec. 24 generated roughly $427 million, according to Akerna (NASDAQ: KERN). The largest sale day of the period was Wednesday, Dec. 23, with $87.3 million, making it the third largest cannabis sales of the year, just behind Green Wednesday with $87.4 million. Exceeding all expectations, New Year’s Eve was the single biggest sales day of 2020 with $89.4 million.

Date: 1-13-21

News10

O’Neill has watched recreational marijuana use become legal in other states, and feels it’s a critical step to stop fueling black markets that sell marijuana products. This way, they can be taxed, and ultimately safer to use.

“You can start regulating the quality and efficacy of the actual product that’s being consumed,” O’Neill said.

Date: 1-13-21

Rochesterfirst.com

Governor Cuomo has announced his plan to legalize recreational marijuana in New York State, and he says the industry will eventually lead to the creation of 60,000 new jobs and $3.5 billion in economic activity.

“You’re going to unleash an incredible amount of demand into the market. It’s a precedent that’s been seen in many, many other states,” said Dennis O’Neill, President of BIOMEDICAN, a biotech startup company that produces rare cannabinoids.

Date: 1-12-21

FoxBusiness

“This is part of a bigger picture that all states will sooner or later legalize cannabis and ultimately the federal government will do so as well,” Dennis O’Neill, the president of BIOMEDICAN, a company that synthesizes cannabinoids, told FOX Business.

Date: 1-7-21

Reuters.com

Cannabis stocks were also boosted on Wednesday by the growing chance of Democratic wins in two pivotal U.S. Senate contests, with investors betting the outcome would make it pave the way for passage of more cannabis-friendly laws in the country

Date : 1-7-21

Nasdaq

Shares of HempFusion Wellness Inc CBDu.TO rose 50% in their debut on the Toronto Stock Exchange on Wednesday, giving the hemp-derived health and wellness products maker a market value of about $176 million.

Date: 1-7-21

YahooFinance

The companies hope to cash in on renewed investor interest after the coronavirus pandemic created a massive demand for cannabis’ relaxative properties.

Date: 1-7-21

WeedWeek

Federal legalization already had unprecedented momentum. The More Act, which would “deschedule” or remove, cannabis from the Controlled Substances Act, passed the Democrat-controlled House of Representatives in December with bipartisan support.

Date : 1-4-21

Cannabis business executive

2020 has been a transformative year for the cannabis industry. A new presidential administration, several states legalizing cannabis, the passage of the MORE Act in the House, and breakthroughs in biosynthesizing rare cannabinoids were just a few major milestones in a turbulent year. As we begin a new year, what developments can we expect for the cannabis industry—particularly the global cannabinoid market?

Date : 12-16-20

Bloomberg Radio

Max Mikheev, Founder and CEO at BioMediCan, discusses the business and benefits of artificial-cannabinoids.

Date : 12-14-20

Mj.com

“The global demand for rare cannabinoids is growing astronomically,” said Biomedican CEO Maxim Mikheev. “We are fully confident we will have the highest quality and lowest cost product in the market.”

Date : 12-8-20

Pharma Almanac

Biosynthesis of rare cannabinoids is one of the fastest growing markets in the world today, and BIOMEDICAN is uniquely positioned with what we believe are the best intellectual property and results in the space.  CBG/CBGA represents the next generation of many new cannabinoids we will be taking to market, and we are fully confident we will have the highest quality, highest yields, and lowest-cost product on the market, which we believe will make us the market leader in the months and years to come.

Date : 12-02-20

Nutra Ingrediants

O’Neill said that while other companies are advertising the capability of producing minor cannabinoids like CBG, in his view the volumes and the pricing of those ingredients will not be competitive with BioMedican’s platform.

“We purposefully stayed away from CBD. Prices have collapsed and it has become a commoditized market full of me-too products,” he said.

Date : 12-2-20

El Planteo

Fortunately, recent innovations in biosynthesis are making THCV easier to produce than ever. Now cannabinoids can be synthesized without plants, resulting in shorter production cycles, less work and energy, and higher yields . The end result is a non-GMO, pharmaceutical grade organic product that is 70-90% cheaper than wholesale prices. Biosynthesis is also more sustainable than plants, since it uses 90% less natural resources and energy.

Date : 11-30-20

Benzinga

THCV produced through biosynthesis can also be added to any edible with zero modifications, which will give it a major advantage in the food and beverage industry. Health food companies will be able to add THCV to a variety of foods and beverages, including protein bars, chocolates, cereals, granola bars, and sports drinks.

Date : 11-30-20

Westword

One biotech company is looking to shake up the cannabinoid-product industry by using biosynthesis to produce rare cannabinoids at a fraction of their current price.

Employing a specialized strain of yeast called Yarrowia lipolytica, California company Biomedican extracts pharmaceutical-grade cannabinoids that are biologically identical to those extracted from plants…

Westword spoke with Biomedican president Dennis O’Neill and CEO Max Mikheev.

Date : 11-18-20

Healthcare Business Today

The global cannabinoid market will take a significant toll on the environment. A kilogram of cannabis releases roughly the same amount of carbon dioxide emissions into the atmosphere as three million U.S. cars. Biosynthesis is at the forefront of a safer, more efficient, and environmentally friendly way to produce rare cannabinoids.

Biomedican has developed a patented method of cannabinoid biosynthesis production from proprietary yeasts. This process produces 100% pure rare cannabinoids without cultivating plants, resulting in cheaper, faster, and more environmentally friendly results.

Date : 11-9-20

Yahoo! Finance (Benzinga pick-up)

“We’re not competing with anybody that’s in that grow, harvest, extract and purify business,” says Biomedican CFO Dennis O’Neill.

The biotech company uses a genetically-modified, proprietary version of yeast to produce cannabinoids without the need for cannabis plants. The resulting cannabinoids are said to be bio-identical to the molecules that can be found in nature.

“We produce 99% pharmaceutical grade products,” says O’Neill. While the method used by Biomedican employs GMO yeast, the final product does not contain any of it, which is why the company can claim its cannabinoids are organic and GMO-free.

Date : 11-6-20

Proactive Investors

Biomedican Inc Chief Investment Officer Dennis O’Neill tells Proactive the Fremont, California-based CBD-focused group is focusing on commercializing its organic, non-GMO CBD compound.

O’Neill says because its CBD product produces 0.0% THC, it opens up distribution channels for the group. The group is expected to begin large-scale production in 2021.

Date : 10-30-20

Inquirer.Net (Reuters pick-up)

“Biosynthetic cannabinoid maker Biomedican has also laid out plans to go public in the first half of 2021″

Date : 10-29-20

Green Entrepreneur (Reuters pick-up)

“By creating biosynthetic cannabis compounds, companies also skip any issues using the real cannabis plant, which remains illegal at the federal level. And the costs are dramatically lower. Biomedican, a company that is working in this area, claims that they have 70 to 90 percent lower production costs than cannabis farms.”

Date : 10-27-20

NJ.com

“All the federal and state regulations are around touching the plant and producing THC at any point in time,” said Dennis O’Neill, chief investment officer of California-based Biomedican. “That creates a big opportunity for us because these rare cannabinoids are the next generations of CBGs.”

Date : 10-26-20

Drug Topics

“Rare cannabinoids like CBG/CBGA, CBN/CBNA, THCV/THCVA, and THCA all have significant evidence of major health benefits. For example, there have been many clinical trials on CBG/CBGA indicating its potential to help fight inflammation, pain, and nausea.”  Maxim Mikheev, CEO and Founder of Biomedican, a biotech startup designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts.

Date : 10-16-20

Ganjaprenerr (Reuters pick-up)

Multiple hemp and cannabis firms say they are planning initial public offerings under the assumption that Joe Biden will win the presidential election next month.

Date : 10-15-20

Reuters

NEW YORK (Reuters) – A year ago, Flora Growth Chief Executive Damian Lopez had just spent a chunk of his company’s seed capital buying a Colombian cannabis producer, and was fighting his way through the legal and financial hurdles that have made development of the industry such a challenge over the past decade.

Date : 10-12-20

Benzinga

Dennis O’Neill, co-founder and CIO of California-based biotech startup Biomedican elaborated: “[CBD and THC] are known because plants can produce them in large quantities, which makes them significantly more affordable.”

Date : 10-8-20

The Philadelphia Inquirer

“Right now, making CBD means you’re in the farming business. By the time you harvest and extract and factor in the purification, it’s expensive,” said Dennis O’Neill, Biomedican‘s chief investment officer. “And you can’t even produce the exact same product every time.”

Date : 10-8-20

Dope Magazine (Bloomberg pick-up)

Fremont, California-based Biomedican has the means to produce CBG in large quantities.  “Right now, making CBD means you’re in the farming business,” Dennis O’Neill, Biomedican’s chief investment officer, told Bloomberg. “By the time you harvest and extract and factor in purification, it’s expensive. And you can’t even produce the exact same product every year.”

Date : 10-4-20

Bloomberg

Biomedican says it will soon be able to produce multiple strains at a similar cost [under $1 a gram], far below CBG’s current wholesale price of $20 a gram. “This is the next generation of CBD,” Dennis O’Neill said.

Date : 9-28-20

Nasdaq

“CBD will become an afterthought as more potent cannabinoids replace it in medicine, beauty products, food and beverages, and more. Rare cannabinoids like CBG, THCA, CBN, THCV, and more will all contribute to this shift, with CBG being the most highly desired for its versatile applications in both the pharmaceutical and food/beverage industries.” Maxim Mikheev, CEO and Founder of Biomedican, a biotech startup designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts.

Date : 9-17-20

Forbes

“According to Dennis O’Neill, chief investment officer at Biomedican, when it comes to producing rare cannabinoids, the grow-harvest-extract method is not only costly; it’s unreliable. Instead, the firm uses biosynthesis, a natural process that O’Neill likens to brewing beer, to grow rare pharmaceutical-grade cannabinoids at scale.”

Date : 9-12-20

Axios

Biosynthesis companies will be able to produce expensive cannabinoids at a much lower price and without fears of contamination. “We can harvest every day, as opposed to a plant that requires 55 days to grow,” says Dennis O’Neill, chief investment officer at Biomedican – biotech startup.

Date : 9-8-20

Biofuels Digest

“Biomedican developed a unique method of cannabinoid biosynthesis production from proprietary yeasts. This process produces high-quality rare cannabinoids without plants, resulting in cheaper, faster, and more sustainable results.”